• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Drugs of today: Medicamentos de actualidad >Lumateperone: a new treatment approach for neuropsychiatric disorders.
【24h】

Lumateperone: a new treatment approach for neuropsychiatric disorders.

机译：LumateParone：神经精神障碍的新治疗方法。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Lumateperone tosylate (ITI-007 tosylate, ITI-722) is a first-in-class investigational drug which acts syn-ergistically through multiple systems (serotonergic, dopaminergic and glutamatergic), thus representing a unique approach for the therapeutic management of a range of neuropsychiatric disorders. It possesses a potent antagonistic activity at 5-hydroxytryptamine (serotonin) 2A (5-HT2A) receptors and also binds to dopamine (D1, D2) receptors with partial agonism at presynaptic D2 receptors and postsynaptic antagonism. Further, preclinical data demonstrated that lumateperone uniquely acts as an indirect modulator of glutamatergic phosphoprotein with D1-dependent augmentation of both NMDA and AMPA activity via the mammalian target of rapamycin (mTOR) pathway, mechanisms thought to predict potent and rapid antidepressant effects. Previous results of schizophrenia efficacy studies found robust improvements in depressive as well as psychotic symptoms for those patients who were comorbidly depressed. In various clinical trials to date, the safety profile of lumateperone was found to be similar to that of placebo. These promising results and strong performance in phase II studies point to the potential of lumateperone to display potent and rapid antidepressant effects in patients suffering from a range of mood disorders. Currently, this novel drug is in phase III of its clinical development for schizophrenia, agitation associated with dementia and bipolar depression.
机译：Lumateperone Tosylate（ITI-007甲苯磺酸酯，ITI-722）是一流的调查药物，其通过多种系统（Serotonergic，多巴胺能和谷氨酸）同步，从而代表了各种各样的治疗管理的独特方法神经精神障碍。它在5-羟基 - 羟基胺（Serotonin）2A（5-HT2A）受体中具有有效的拮抗活性，并且还与突触前D2受体和突触拮抗作用的部分激动的多巴胺（D1，D2）受体结合。此外，临床前数据表明，百叶草酸作为谷氨酸磷蛋白的间接调节剂，其通过哺乳动物催留毒素（MTOR）途径的哺乳动物靶标的D1依赖性增强，旨在预测有效和快速的抗抑郁作用。精神分裂症疗效研究的先前结果发现，对那些令人沮丧的患者的抑郁以及精神病症状有鲁棒的改善。在迄今为止的各种临床试验中，发现Lumateperone的安全性曲线与安慰剂相似。这些有希望的结果和II期研究表现强的表现，对患有一系列情绪障碍的患者显示有效和快速的抗抑郁作用的潜在患者。目前，这种新型药物是其对精神分裂症的临床开发的III期，与痴呆和双相抑郁症相关的搅拌。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号